ArticleMolecular therapy : the journal of the American Society of Gene Therapy2009
Determination of the fate and contribution of ex vivo expanded human bone marrow stem and progenitor cells for bone formation by 2.3ColGFP.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- A Rras2-BMPR2 feedback loop sustains osteogenesis and represents a therapeutic target for osteoporosis.Nature communications · 2026Article
- Research Progress of Bone Grafting: A Comprehensive Review.International journal of nanomedicine · 2025Review
- Comparison of concentrated fresh mononuclear cells and cultured mesenchymal stem cells from bone marrow for bone regeneration.Stem cells translational medicine · 2021Article
- Stepwise strategy for generating osteoblasts from human pluripotent stem cells under fully defined xeno-free conditions with small-molecule inducers.Regenerative therapy · 2020Article
- 1,25-Dihydroxyvitamin D protects against age-related osteoporosis by a novel VDR-Ezh2-p16 signal axis.Aging cell · 2020Article
- Bone Marrow Mononuclear Cells Combined with Beta-Tricalcium Phosphate Granules for Alveolar Cleft Repair: A 12-Month Clinical Study.Scientific reports · 2017Article
- A Site-Specific Integrated Col2.3GFP Reporter Identifies Osteoblasts Within Mineralized Tissue Formed In Vivo by Human Embryonic Stem Cells.Stem cells translational medicine · 2014Article
- New bio-ceramization processes applied to vegetable hierarchical structures for bone regeneration: an experimental model in sheep.Tissue engineering. Part A · 2014Article
- One-pot synthesis of magnetic nanoclusters enabling atherosclerosis-targeted magnetic resonance imaging.International journal of nanomedicine · 2014Article
- Potential beneficial effects of ixmyelocel-T in the treatment of atherosclerotic diseases.Stem cell research & therapy · 2013Article
- Visualizing osteogenesis in vivo within a cell-scaffold construct for bone tissue engineering using two-photon microscopy.Tissue engineering. Part C, Methods · 2013Article
- Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages.Stem cell research & therapy · 2013Article
- Bone repair cells for craniofacial regeneration.Advanced drug delivery reviews · 2012Review
- The Aastrom experience.Stem cell research & therapy · 2012Review
- Ectopic expression of SOX9 in osteoblasts alters bone mechanical properties.Calcified tissue international · 2012Article
- Article
- Cell therapy in bone healing disorders.Orthopedic reviews · 2010Article
- [Cell therapy in bone-healing disorders].Der Orthopade · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow transplantation can provide an effective cell-based strategy to enhance bone repair. However, the fate of implanted cells and the extent of their contribution to bone osteoinduction remain uncertain. To define the fate of bone marrow-derived cells and their contribution in vivo, we used a bone-specific collagen I promoter (2.3Col) driving green fluorescent protein (GFP) (2.3ColGFP) within a lentiviral vector. Prior to in vivo cell fate determination, we verified a high efficiency of lentiviral transduction in human bone marrow stromal cells (hBMSCs), without altering the proliferation or differentiation potential of these cells. We showed that the 2.3ColGFP marker responded to endogenous transcriptional regulation signals. In a mouse ossicle model, we demonstrated that the 2.3ColGFP marker is able to specifically define human bone marrow-derived stem cells that enter the osteoblast lineage in vivo. In addition, cells labeled with 2.3ColGFP with the donor origin, directly make a major contribution to bone formation. Furthermore, we also demonstrated in a calvarial defect model that a mixture of human bone marrow-derived populations, have stronger bone regenerative potential than that of hBMSCs, and an optimal dose is required for bone regeneration by the mixed populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.